Clinical trials: Hepatic Function
Hepatic Impairment, Healthy
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate Hepatic impairment compared to subjects with normal hepatic function
- Trial name
- NCT03289234
- Testing
- MCI-186
- Where
- 2 sites in Japan
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Shionogi
Participants Scheduled for Surgery Under Spinal Anesthesia Without Impairment of Renal, Hepatic, Cardiac or Respiratory Function
Autonomic Modulation After Spinal Anesthesia With Depth of Anesthesia and Vital Signs.
Spinal anaesthesia has the advantage that produced nerve block by the injection of local anaesthetic into cerebrospinal fluid (CSF).
- Trial name
- NCT04275375
- Testing
- observation study about the autonomic response after spinal anesthesia
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- National Central University
Hepatic Insufficiency
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Assessment of the effect of moderate liver impairment (Child-Pugh classification B) on the pharmacokinetics and pharmacodynamics of dabigatran after oral administration of dabigatran etexilate.
- Trial name
- NCT02170571
- Testing
- Dabigatran etexilate
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Amenorrhea
Determination of the Lowest, Safe and Effective Dose of Proellex
The purpose of this study is to determine the effects of five different doses of Proellex on menses, ovulation, liver function, and steady state exposure in women of reproductive age.
- Trial name
- NCT01187043
- Testing
- Proellex
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.
- Trial name
- NCT05517525
- Testing
- Brensocatib
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Magnetic Resonance Technics for the Assessment of Liver Function Before and After TIPS
Portal hypertension is the end-stage fatal complications of liver cirrhosis. Decompensated cirrhosis patients can pass through transjugular intrahepatic portosystemic shunt to effectively prevent bleeding and refractory ascites.
- Conditions
- Liver Cirrhosis, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Functional Magnetic Resonance Imaging
- Trial name
- NCT03933891
- Testing
- TIPS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- West China Hospital
Healthy Participants, Hepatic Impairment
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
- Trial name
- NCT07751250
- Testing
- Casdatifan
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Arcus Biosciences, Inc.
Spinal and Bulbar Muscular Atrophy (SBMA), Motor Neuron Disease
Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Background: Spinal and bulbar muscular atrophy (SBMA) is an inherited disease. It causes weakness in muscles used for swallowing, breathing, and speaking. SBMA mainly affects men, but women can carry the gene for it.
- Trial name
- NCT02124057
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Liver Diseases, Healthy
Validation of Point of Care Liver Function Tests
This study is testing the accuracy of a point of care device that tests liver function within 20 minutes. The target population will be any adult who had liver function tests ordered and to be drawn on the same day as enrollment.
- Conditions
- Liver Diseases, Healthy, Cirrhosis, Liver, Fibrosis
- Trial name
- NCT03800069
- Testing
- Group K Diagnostic point of care device
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Healthy
Dose-dependent Kinetics of Thiamin in Healthy Volunteers With and Without Functional OCT1 Hepatic Transporters
This study investigates the differences in thiamin (vitamin B1) kinetic parameters in two cohorts of healthy volunteers: Cohort 1) OCT1 wild type genotypes n = 12 Cohort 2) OCT1 deficient genotypes n = 12 Participants will be…
- Trial name
- THIAMO-1 (NCT06122701)
- Testing
- Thiamin p.o., Thiamin i.v.
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Hepatic Impairment
Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
This is an open-label, single-dose study designed to assess the pharmacokinetics and safety of ABT-493 and/or ABT-530 in subjects with impaired hepatic function and compare them to those in subjects with normal hepatic function.
- Trial name
- NCT02296905
- Testing
- ABT-493, ABT-530
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Autoimmune Liver Disease
Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease
This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department of Liver Diseases, Beijing…
- Trial name
- NCT04028869
- Testing
- Glycyrrhizic acid preparation
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Ditan Hospital
Patients With Impaired Hepatic Function
Pharmacokinetics Study in Patients With Impaired Hepatic Function
The objective of this study is to compare and evaluate the pharmacokinetics of ASP015K in patients with impaired hepatic function and subjects with normal hepatic function.
- Trial name
- NCT02586194
- Testing
- ASP015K
- Where
- 6 sites in Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Menopause, Non Alcholic Fatty Liver Disease
MHT and Liver Function in Postmenopausal Women
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women.
- Conditions
- Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis
- Trial name
- NCT07103603
- Testing
- Menopausal hormone therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Ipek B. Ozcivit Erkan, MD
Hepatic Insufficiency
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.
- Trial name
- NCT06858696
- Testing
- Mavorixafor
- Where
- 4 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- X4 Pharmaceuticals
Clostridium Difficile Infection, Multi Drug Resistant Organisms
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects with Clostridium Difficile (CDI), subjects affected by Multi Drug Resistant Organisms (MDRO) infection…
- Conditions
- Clostridium Difficile Infection, Multi Drug Resistant Organisms, Chronic Inflammatory Bowel Disease, Irritable Bowel Syndrome
- Trial name
- BIOMIS-Gastr (NCT04698148)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 3 sites in Italy
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Advanced Malignancies
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.
- Trial name
- NCT04831944
- Testing
- parsaclisib
- Where
- 5 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Liver Function Tests Abnormalities
Liver Function Test Abnormalities in COVID-19
With the increasing number of COVID-19 infected patients, several studies reported that the liver is the most frequently affected organ after lung damage.
- Trial name
- COVID-19 (NCT04763395)
- Testing
- No intervention
- Where
- Egypt
- Volunteers
- 118 people
- Sponsor
- Sohag University